DIAN DIAGNOSTICS(SZ:300244)2026-01-13 10:24Group 1: AI in Healthcare - AI is expected to drive rapid development in healthcare applications, particularly in primary care and health management scenarios, although complex conditions and evidence-based medicine require high-quality multimodal data support [1] - AI will benefit patients through comprehensive health management across their life cycle, while serving as an auxiliary tool for doctors to democratize knowledge [1] - The company is implementing a "clinical research + grassroots empowerment" model to promote product deployment [1] Group 2: Market Potential and Revenue - The annual screening volume for cervical cancer in China is approximately 100 to 120 million cases, with charging standards ranging from tens to 200 yuan, averaging around 150 yuan per case in major provinces [2] - The potential market size for mature terminal services is estimated to be in the range of 360 to 1,440 million yuan annually [2] - The company’s AI-related business currently contributes a minimal percentage to overall revenue, indicating it is still in the early stages of development [1] Group 3: Product Differentiation and Certification - The company has established an independent team for comprehensive pathology IVD AI development, demonstrating significant advantages in data scale, quality, algorithm iteration, and clinical application pathways [2] - The company has issued over 6 million real clinical reports, showcasing the practical application of its products [2] - The typical time to obtain a Class III certification in the industry is around 3 to 5 years, while the company achieved this in approximately 3 years due to high-quality data and clinical validation capabilities [2]